ArticleScientific reports2019
Potential population level impact on tuberculosis incidence of using an mRNA expression signature correlate-of-risk test to target tuberculosis preventive therapy.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial.The Lancet. Infectious diseases · 2021Trial
- Host Blood Transcriptional Signatures as Candidate Biomarkers for Predicting Progression to Active Tuberculosis.Tuberculosis and respiratory diseases · 2023Article
- Variance-based sensitivity analysis of tuberculosis transmission models.Journal of the Royal Society, Interface · 2022Article
- Global Tuberculosis Report 2020 - Reflections on the Global TB burden, treatment and prevention efforts.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Article
- Optima TB: A tool to help optimally allocate tuberculosis spending.PLoS computational biology · 2021Article
- BCG vaccine: a hope to control COVID-19 pandemic amid crisis.Human vaccines & immunotherapeutics · 2020Review
- Headway made towards biosignatures for incipient tuberculosis.The Lancet. Respiratory medicine · 2020Article
- Transcriptional biomarkers for predicting development of tuberculosis: progress and clinical considerations.The European respiratory journal · 2020Article
- Host-Directed Therapy as a Novel Treatment Strategy to Overcome Tuberculosis: Targeting Immune Modulation.Antibiotics (Basel, Switzerland) · 2020Review
- Validation of Differentially Expressed Immune Biomarkers in Latent and Active Tuberculosis by Real-Time PCR.Frontiers in immunology · 2020Article
- Neutrophils in Tuberculosis-Associated Inflammation and Lung Pathology.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Achieving the WHO End-Tuberculosis (TB) targets requires approaches to prevent progression to TB among individuals with Mycobacterium tuberculosis (M.tb) infection. Effective preventive therapy (PT) exists, but current tests have low specificity for identifying who, among those infected, is at risk of developing TB. Using mathematical models, we assessed the potential population-level impact on TB incidence of using a new more specific mRNA expression signature (COR) to target PT among HIV-uninfected adults in South Africa. We compared the results to the use of the existing interferon-γ release assay (IGRA). With annual screening coverage of 30% COR-targeted PT could reduce TB incidence in 2035 by 20% (95% CI 15-27). With the same coverage, IGRA-targeted PT could reduce TB incidence by 39% (31-48) but would require greater use of PT resulting in a higher number needed to treat per TB case averted (COR: 49 (29-77); IGRA: 84 (59-123)). The relative differences between COR and IGRA were not sensitive to screening coverage. COR-targeted PT could contribute to reducing total TB burden in high incidence countries like South Africa by allowing more efficient targeting of treatment. To maximise impact, COR-like tests may be best utilised in the highest burden regions, or sub-populations, within these countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.